Combination of Crizotinib and Osimertinib in T790M+EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

被引：6
|
作者：
Blasi, Miriam [1 ]
Kazdal, Daniel [2 ,3 ]
Thomas, Michael [1 ,3 ]
Christopoulos, Petros [1 ,3 ]
Kriegsmann, Mark [2 ,3 ]
Brandt, Regine [2 ]
Volckmar, Anna-Lena [2 ]
Kirchner, Martina [2 ]
Heussel, Claus Peter [3 ,4 ]
Stenzinger, Albrecht [2 ,3 ]
Kuon, Jonas [1 ,3 ]
机构：
[1] Heidelberg Univ, Dept Thorac Oncol, Thoraxklin, Rontgenstr 1, DE-69126 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
[3] German Ctr Lung Res DZL, Translat Lung Res Ctr TLRC Heidelberg, Heidelberg, Germany
[4] Heidelberg Univ, Thoraxklin, Diagnost & Intervent Radiol Nucl Med, Heidelberg, Germany
来源：
CASE REPORTS IN ONCOLOGY | 2021年 / 14卷 / 01期
关键词：
Non-small cell lung cancer; EGFR mutation; MET amplification; Targeted therapy; RESISTANCE; PATIENT; INHIBITORS; GEFITINIB; MECHANISM; AZD9291;
D O I：
10.1159/000513904
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as MET oncogene amplification. This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the multitargeted TKI and MET inhibitor crizotinib in a patient with EGFR-mutant NSCLC with emerging MET amplification with a tolerable toxicity profile.
引用
收藏
页码：477 / 482
页数：6
相关论文
共 50 条
  • [21] Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review
    Wu, Longqiu
    Zhong, Wenjuan
    Li, An
    Qiu, Zhengang
    Xie, Ruilian
    Shi, Huaqiu
    Lu, Shun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (11)
  • [22] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [23] Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
    Nanjo, Shigeki
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Okada, Hideaki
    Tamura, Daisuke
    Irie, Kei
    Okada, Hiroshi
    Fukushima, Shoji
    Katakami, Nobuyuki
    BRITISH JOURNAL OF CANCER, 2018, 118 (01) : 32 - 37
  • [24] High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
    Ariyasu, Ryo
    Nishikawa, Shingo
    Uchibori, Ken
    Oh-hara, Tomoko
    Yoshizawa, Takahiro
    Dotsu, Yosuke
    Koyama, Junji
    Saiki, Masafumi
    Sonoda, Tomoaki
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Inase, Naohiko
    Kasahara, Kazuo
    Nishio, Makoto
    Katayama, Ryohei
    LUNG CANCER, 2018, 117 : 1 - 6
  • [25] Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease
    Arulananda, Surein
    Do, Hongdo
    Rivalland, Gareth
    Loh, Zoe
    Musafer, Ashan
    Lau, Eddie
    Mitchell, Paul
    Dobrovic, Alexander
    John, Thomas
    JOURNAL OF THORACIC DISEASE, 2019, 11 (05) : 1756 - 1764
  • [26] Genomic Profiling of EGFR T790M Mutated Non-Small Cell Lung Cancer to Evaluate the Mechanisms of Resistance to Osimertinib
    Puri, S.
    Hicks, J.
    Knepper, T.
    Smith, M.
    Boyle, T.
    Gray, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1848 - S1849
  • [27] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [28] The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis
    Guo, Liuxian
    Zhou, Guojin
    Huang, Min
    Tang, Kejing
    Xu, Jing
    Chen, Jie
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (04)
  • [29] Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
    Pina, Pamela Soberanis
    Lara-Mejia, Luis
    Matias-Cruz, Venecia
    Barron, Feliciano
    Cardona, Andres F.
    Raez, Luis E.
    Rios-Garcia, Eduardo
    Arrieta, Oscar
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
12345